Cargando…

Investigating fecal microbial transplant as a novel therapy in dogs with inflammatory bowel disease: A preliminary study

BACKGROUND: There are limited studies investigating the use of fecal microbial transplant (FMT) in dogs with inflammatory bowel disease (IBD). The aim of this preliminary study was to assess the feasibility of adding FMT to standard therapy (corticosteroids and a hypoallergenic diet) for dogs with I...

Descripción completa

Detalles Bibliográficos
Autores principales: Collier, Allison J., Gomez, Diego E., Monteith, Gabrielle, Plattner, Brandon L., Verbrugghe, Adronie, Webb, Jinelle, Weese, J. Scott, Blois, Shauna L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578606/
https://www.ncbi.nlm.nih.gov/pubmed/36256653
http://dx.doi.org/10.1371/journal.pone.0276295
_version_ 1784811999028314112
author Collier, Allison J.
Gomez, Diego E.
Monteith, Gabrielle
Plattner, Brandon L.
Verbrugghe, Adronie
Webb, Jinelle
Weese, J. Scott
Blois, Shauna L.
author_facet Collier, Allison J.
Gomez, Diego E.
Monteith, Gabrielle
Plattner, Brandon L.
Verbrugghe, Adronie
Webb, Jinelle
Weese, J. Scott
Blois, Shauna L.
author_sort Collier, Allison J.
collection PubMed
description BACKGROUND: There are limited studies investigating the use of fecal microbial transplant (FMT) in dogs with inflammatory bowel disease (IBD). The aim of this preliminary study was to assess the feasibility of adding FMT to standard therapy (corticosteroids and a hypoallergenic diet) for dogs with IBD and to and to describe the changes in measured outcomes after 30 days of treatment. METHODS: Thirteen client-owned dogs with IBD were enrolled in this double blinded, randomized clinical trial. All dogs received corticosteroid therapy and a hypoallergenic diet; dogs were randomized to receive either placebo or FMT. Measured outcomes included the canine chronic enteropathy clinical activity index (CCECAI) at 1 week and 1 month after enrolment. Fecal microbiota were analyzed after extracting DNA from fecal samples and profiling using 16S amplicon sequencing. Dogs in the placebo group not responding to treatment after 1 month were offered FMT. RESULTS: The CCECAI significantly decreased over time in both groups (p = 0.001). There were no significant differences between the CCECAI of the placebo and FMT group at each time point (F test from ANOVA, p = 0.40). No adverse effects were reported in the 30 days following FMT. CONCLUSIONS: The addition of FMT to standard therapy for IBD was feasible. No significant differences were observed in the CCECAI between groups at each time point. Large scale clinical trials can be performed using these methods to evaluate the longer term effect of FMT on clinical signs, microbial diversity, and other outcomes.
format Online
Article
Text
id pubmed-9578606
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-95786062022-10-19 Investigating fecal microbial transplant as a novel therapy in dogs with inflammatory bowel disease: A preliminary study Collier, Allison J. Gomez, Diego E. Monteith, Gabrielle Plattner, Brandon L. Verbrugghe, Adronie Webb, Jinelle Weese, J. Scott Blois, Shauna L. PLoS One Research Article BACKGROUND: There are limited studies investigating the use of fecal microbial transplant (FMT) in dogs with inflammatory bowel disease (IBD). The aim of this preliminary study was to assess the feasibility of adding FMT to standard therapy (corticosteroids and a hypoallergenic diet) for dogs with IBD and to and to describe the changes in measured outcomes after 30 days of treatment. METHODS: Thirteen client-owned dogs with IBD were enrolled in this double blinded, randomized clinical trial. All dogs received corticosteroid therapy and a hypoallergenic diet; dogs were randomized to receive either placebo or FMT. Measured outcomes included the canine chronic enteropathy clinical activity index (CCECAI) at 1 week and 1 month after enrolment. Fecal microbiota were analyzed after extracting DNA from fecal samples and profiling using 16S amplicon sequencing. Dogs in the placebo group not responding to treatment after 1 month were offered FMT. RESULTS: The CCECAI significantly decreased over time in both groups (p = 0.001). There were no significant differences between the CCECAI of the placebo and FMT group at each time point (F test from ANOVA, p = 0.40). No adverse effects were reported in the 30 days following FMT. CONCLUSIONS: The addition of FMT to standard therapy for IBD was feasible. No significant differences were observed in the CCECAI between groups at each time point. Large scale clinical trials can be performed using these methods to evaluate the longer term effect of FMT on clinical signs, microbial diversity, and other outcomes. Public Library of Science 2022-10-18 /pmc/articles/PMC9578606/ /pubmed/36256653 http://dx.doi.org/10.1371/journal.pone.0276295 Text en © 2022 Collier et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Collier, Allison J.
Gomez, Diego E.
Monteith, Gabrielle
Plattner, Brandon L.
Verbrugghe, Adronie
Webb, Jinelle
Weese, J. Scott
Blois, Shauna L.
Investigating fecal microbial transplant as a novel therapy in dogs with inflammatory bowel disease: A preliminary study
title Investigating fecal microbial transplant as a novel therapy in dogs with inflammatory bowel disease: A preliminary study
title_full Investigating fecal microbial transplant as a novel therapy in dogs with inflammatory bowel disease: A preliminary study
title_fullStr Investigating fecal microbial transplant as a novel therapy in dogs with inflammatory bowel disease: A preliminary study
title_full_unstemmed Investigating fecal microbial transplant as a novel therapy in dogs with inflammatory bowel disease: A preliminary study
title_short Investigating fecal microbial transplant as a novel therapy in dogs with inflammatory bowel disease: A preliminary study
title_sort investigating fecal microbial transplant as a novel therapy in dogs with inflammatory bowel disease: a preliminary study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578606/
https://www.ncbi.nlm.nih.gov/pubmed/36256653
http://dx.doi.org/10.1371/journal.pone.0276295
work_keys_str_mv AT collierallisonj investigatingfecalmicrobialtransplantasanoveltherapyindogswithinflammatoryboweldiseaseapreliminarystudy
AT gomezdiegoe investigatingfecalmicrobialtransplantasanoveltherapyindogswithinflammatoryboweldiseaseapreliminarystudy
AT monteithgabrielle investigatingfecalmicrobialtransplantasanoveltherapyindogswithinflammatoryboweldiseaseapreliminarystudy
AT plattnerbrandonl investigatingfecalmicrobialtransplantasanoveltherapyindogswithinflammatoryboweldiseaseapreliminarystudy
AT verbruggheadronie investigatingfecalmicrobialtransplantasanoveltherapyindogswithinflammatoryboweldiseaseapreliminarystudy
AT webbjinelle investigatingfecalmicrobialtransplantasanoveltherapyindogswithinflammatoryboweldiseaseapreliminarystudy
AT weesejscott investigatingfecalmicrobialtransplantasanoveltherapyindogswithinflammatoryboweldiseaseapreliminarystudy
AT bloisshaunal investigatingfecalmicrobialtransplantasanoveltherapyindogswithinflammatoryboweldiseaseapreliminarystudy